Pliant Therapeutics
Pliant Therapeutics Logo
About Pliant Therapeutics
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for the treatment of fibrosis and related diseases. Its lead candidate, bexotegrast, is an oral, small-molecule dual selective inhibitor of avß6 and avß1 integrins, in phase 2b trials for idiopathic pulmonary fibrosis and phase 2a for primary sclerosing cholangitis. The company is also developing PLN-1474 for liver fibrosis, PLN-101095 for solid tumors, and PLN-101325 for muscular dystrophies. Pliant's approach targets fibrotic tissue-specific inhibition of integrins and the TGF-β pathway.
Address
260 Littlefield Avenue,
South San Francisco, 94080
United States
Year founded
2015
Number of employees
100-200
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Report inaccurate data
Request an update to help us keep the brand up-to-date.
